Isopentyl caffeate as a promising drug for the treatment of leishmaniasis: An in silico and in vivo study

Isopentyl caffeate as a promising drug for the treatment of leishmaniasis: An in silico and in vivo study

Leishmaniasis is recognised as the second largest parasitic disease worldwide and yet a neglected disease. The current pharmacological treatments are associated with significant challenges, including high toxicity, high cost and parasitic resistance. Considering the potential of isopentyl caffeate (...

Full description

Bibliographic Details
Main Authors: Wanessa S. Mota, Simone S.C. Oliveira, Matheus M. Pereira, Damião P. Souza, Mayara Castro, Pollyanna S. Gomes, Herbert L.M. Guedes, Vinícius F. Souza, André L.S. Santos, Ricardo L.C. Albuquerque-Junior, Juliana C. Cardoso, Cristina Blanco-Llamero, Sona Jain, Eliana B. Souto, Patrícia Severino
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Current Research in Biotechnology
Subjects:
Leishmania
Isopentyl caffeate
In silico
Pharmacokinetics
ADME
Bioavailability
Online Access:http://www.sciencedirect.com/science/article/pii/S2590262824000352

Similar Items

Similar Items